Glofitamab is a bispecific antibody containing a special structure created by Roche, which has two domains that can attach to CD20 and one that attaches to CD3. The structure and mechanism of ...

To define the molecular basis for rituximab resistance we developed several RRCL and demonstrated changes in CD20 expression/structure and membrane reorganization following rituximab therapy.

The CD20 protein presents a unique arrangement, featuring four membrane-spanning domains. Notably, both the amino and carboxy termini of the protein are positioned within the cytoplasm. An intriguing ...

An incisional biopsy reveals a diffuse large B-cell lymphoma, and immunohistochemical staining is positive for the B-cell antigen CD20 ... In the lower inset, the structure of chimeric and ...

Therapeutic monoclonal antibodies (mAbs) are used in chronic lymphocytic leukemia immunotherapies to target the receptor CD20 at the plasma membrane of immunological B cells. Although they have ...

Antibodies directed against the protein CD20, which is expressed by immune cells known as B cells, are used to treat B cell non-Hodgkin lymphoma and rheumatoid arthritis. Despite this, the ...

BAT4306F is an ADCC-enhanced CD20 monoclonal antibody that has demonstrated enhanced potency in preclinical studies with potential to be a “best-in-class” therapeutic. “Initiating our Phase ...